Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leukemia, Myeloid, Acute × ficlatuzumab × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lip Neoplasms 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 196 Azacitidine 140 Cyclophosphamide 135 fludarabine phosphate 110 fludarabine 95 Busulfan 95 venetoclax 93 Mycophenolic Acid 81 Whole-Body Irradiation 80 Peripheral Blood Stem Cell Transplantation 77 Tacrolimus 76 Decitabine 62 Filgrastim 56 Granulocyte Colony-Stimulating Factor 54 Cyclosporine 52 Methotrexate 51 Melphalan 51 Idarubicin 51 Daunorubicin 48 Antilymphocyte Serum 47 Clofarabine 42 Etoposide 41 Thiotepa 34 Gemtuzumab 34 Mitoxantrone 32 Stem Cell Transplantation 31 CPX-351 27 Radiotherapy 25 thymoglobulin 24 Specimen Handling 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡